论文部分内容阅读
目的探讨同步放化疗加巩固化疗方案在非小细胞肺癌治疗中的临床应用价值。方法将85例Ⅲ期非小细胞肺癌(NSCLC)患者按照随机分层分组法分为观察组和对照组,对照组给予序贯放化疗方案,观察组给予同步放化疗加巩固化疗方案,观察两组临床症状改善情况、近期疗效、血清肿瘤标志物水平、1、3年生存率和中位生存时间。结果观察组患者临床症状改善情况及血清肿瘤标志物水平均优于对照组,差异有统计学意义(P<0.05)。观察组患者临床有效率和受益率均明显高于对照组,差异有统计学意义(P<0.05)。随访3年,观察组和对照组1年生存率的差异无统计学意义(P>0.05),但观察组3年生存率及中位生存时间均高于对照组,差异有统计学意义(P<0.05)。结论同步放化疗加巩固化疗能显著改善NSCLC临床症状,降低血清肿瘤标志物水平,提高近期疗效和远期生存率,在NSCLC治疗中有重要意义。
Objective To investigate the clinical value of concurrent chemoradiotherapy plus consolidation chemotherapy in the treatment of non-small cell lung cancer. Methods Eighty-five patients with stage Ⅲ non-small cell lung cancer (NSCLC) were divided into observation group and control group according to randomized stratified grouping. The control group received sequential radiotherapy and chemotherapy regimen, while the observation group received concurrent chemoradiotherapy and consolidation chemotherapy. Group clinical symptoms improved, short-term efficacy, serum tumor markers, 1, 3-year survival rate and median survival time. Results The improvement of clinical symptoms and the level of serum tumor markers in observation group were better than those in control group (P <0.05). The clinical efficiency and benefit rate of the observation group were significantly higher than that of the control group, the difference was statistically significant (P <0.05). The follow-up of 3 years, the observation group and control group 1-year survival rate was no significant difference (P> 0.05), but the observation group 3-year survival rate and median survival time were higher than the control group, the difference was statistically significant (P <0.05). Conclusions Concurrent chemoradiotherapy plus consolidation chemotherapy can significantly improve the clinical symptoms, reduce the level of serum tumor markers and improve the short-term efficacy and long-term survival rate, which is of great significance in the treatment of NSCLC.